FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317884301> ?p ?o ?g. }

• W4317884301 endingPage "204209862211432" @default.
• W4317884301 startingPage "204209862211432" @default.
• W4317884301 abstract "National regulatory systems in Southern Africa reflect various stages of maturity, and pharmacovigilance (PV) practices are not aligned. In the absence of guidance for formulating PV guidelines in Southern African Development Community (SADC) countries, this study aimed to create a checklist that may be used to assess the rigour of PV guidelines in this region and provide guidance for the National Medicines Regulatory Agency (NMRA) authors.A document analysis was performed based on harmonised international guidelines (n = 22) that prescribed methods of PV regulation to identify themes and items to incorporate into a checklist. The contextualisation of the checklist to the African pharmaceutical environment was accomplished by referencing peer-reviewed journal articles (n = 7). The checklist was subjected to face and content validation by non-experts and PV experts.The document review yielded 5 themes, 18 sub-themes, and 73 items structured into the checklist. Themes encompassed PV systems, definitions, individual case safety reporting, aggregate reporting, and risk management. Under PV systems, aspects of the quality management system were outlined, that is, the legal basis for PV, a description of the marketing authorisation holder's (MAH's) PV system, archiving of data, contracting of PV tasks, and the duties of the person responsible for the MAH's PV obligations. Definitions of the key terms and major stakeholders were identified. Reporting of individual case safety reports (ICSRs) was explicated by considering the criteria for reporting, categories of reportable information, expedited reporting requirements, reporting timelines, and ICSR reporting format. Aggregate report submission during the development and post-marketing phases was addressed. Risk management encompassed signal detection, re-evaluation of the benefit-risk ratio, the safety decision-making process, risk management planning, risk minimisation and safety communication.The developed checklist can contribute towards assisting SADC NMRAs to formulate national PV guidelines that reflect current international practice, with local context incorporated.Developing a checklist for the evaluation of medicine safety guidelines in Southern AfricaIntroduction: In Southern African Development Community (SADC) countries, the guidelines for medicine safety [pharmacovigilance (PV)] that marketing authorisation holders (MAHs) and healthcare professionals need to adhere to, are not aligned. We saw the need to develop a checklist that can be used to evaluate these guidelines.Methods: We studied international documents issued by the World Health Organization (WHO), the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), the Council for International Organizations of Medical Sciences (CIOMS) and the European Medicines Agency (EMA). On the organisational websites, we obtained 22 documents and identified 73 checklist items. All the items were arranged under 5 themes and 18 sub-themes to create the checklist. We adapted the checklist to the local context by using seven journal articles addressing PV concerns in Africa. Experts checked the content and usability of the checklist.Results: The themes were PV systems, definitions, individual case safety reporting (ICSR), combined reporting and risk management. PV systems had six sub-themes: legal structure, description of the MAH's PV system, contractual agreements, information storage, the qualified person responsible for PV (QPPV) and where the QPPV is located. We included the definitions of keywords and role-players. The ICSR theme had five sub-themes, i.e. criteria for reporting, categories of reportable information, expedited reporting, reporting timelines, and reporting format. Submission of summary reports comprised an overview of the safety profile of a medicine once it is approved by regulators, as well as during clinical trials. Risk management included signal detection, re-evaluation of the benefit-risk ratio, safety decision-making process, risk management planning, risk minimisation, and safety communication. The checklist is applied by allocating yes/no scoring per item.Conclusion: The checklist may be used by regulators within SADC to assess their PV guidelines for alignment with international standards and suitability to the local environment." @default.
• W4317884301 created "2023-01-25" @default.
• W4317884301 creator A5007664407 @default.
• W4317884301 creator A5024149036 @default.
• W4317884301 creator A5040666262 @default.
• W4317884301 creator A5052070624 @default.
• W4317884301 creator A5089632050 @default.
• W4317884301 date "2023-01-01" @default.
• W4317884301 modified "2023-10-02" @default.
• W4317884301 title "Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review" @default.
• W4317884301 cites W1924618820 @default.
• W4317884301 cites W1957980836 @default.
• W4317884301 cites W2037721798 @default.
• W4317884301 cites W2084267788 @default.
• W4317884301 cites W2107064318 @default.
• W4317884301 cites W2114984525 @default.
• W4317884301 cites W2275701066 @default.
• W4317884301 cites W2312940223 @default.
• W4317884301 cites W2736849112 @default.
• W4317884301 cites W2748793112 @default.
• W4317884301 cites W2764210732 @default.
• W4317884301 cites W2765286483 @default.
• W4317884301 cites W2883273322 @default.
• W4317884301 cites W2899441429 @default.
• W4317884301 cites W2900284063 @default.
• W4317884301 cites W2901087969 @default.
• W4317884301 cites W2935222413 @default.
• W4317884301 cites W2950143952 @default.
• W4317884301 cites W2955293402 @default.
• W4317884301 cites W2981920519 @default.
• W4317884301 cites W3000230954 @default.
• W4317884301 cites W3017036109 @default.
• W4317884301 cites W3022467550 @default.
• W4317884301 cites W3040602412 @default.
• W4317884301 cites W3048395678 @default.
• W4317884301 cites W3087583759 @default.
• W4317884301 cites W3092304652 @default.
• W4317884301 cites W3105724865 @default.
• W4317884301 cites W3134329898 @default.
• W4317884301 cites W3136351346 @default.
• W4317884301 cites W3188567152 @default.
• W4317884301 cites W4200425697 @default.
• W4317884301 cites W4205391316 @default.
• W4317884301 doi "https://doi.org/10.1177/20420986221143272" @default.
• W4317884301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36713000" @default.
• W4317884301 hasPublicationYear "2023" @default.
• W4317884301 type Work @default.
• W4317884301 citedByCount "1" @default.
• W4317884301 countsByYear W43178843012023 @default.
• W4317884301 crossrefType "journal-article" @default.
• W4317884301 hasAuthorship W4317884301A5007664407 @default.
• W4317884301 hasAuthorship W4317884301A5024149036 @default.
• W4317884301 hasAuthorship W4317884301A5040666262 @default.
• W4317884301 hasAuthorship W4317884301A5052070624 @default.
• W4317884301 hasAuthorship W4317884301A5089632050 @default.
• W4317884301 hasBestOaLocation W43178843011 @default.
• W4317884301 hasConcept C108170787 @default.
• W4317884301 hasConcept C111472728 @default.
• W4317884301 hasConcept C138885662 @default.
• W4317884301 hasConcept C15744967 @default.
• W4317884301 hasConcept C166957645 @default.
• W4317884301 hasConcept C180747234 @default.
• W4317884301 hasConcept C197934379 @default.
• W4317884301 hasConcept C2524010 @default.
• W4317884301 hasConcept C2779356329 @default.
• W4317884301 hasConcept C2779530757 @default.
• W4317884301 hasConcept C33923547 @default.
• W4317884301 hasConcept C41008148 @default.
• W4317884301 hasConcept C4438859 @default.
• W4317884301 hasConcept C509550671 @default.
• W4317884301 hasConcept C56739046 @default.
• W4317884301 hasConcept C57658597 @default.
• W4317884301 hasConcept C71008984 @default.
• W4317884301 hasConcept C71924100 @default.
• W4317884301 hasConcept C95457728 @default.
• W4317884301 hasConcept C98274493 @default.
• W4317884301 hasConceptScore W4317884301C108170787 @default.
• W4317884301 hasConceptScore W4317884301C111472728 @default.
• W4317884301 hasConceptScore W4317884301C138885662 @default.
• W4317884301 hasConceptScore W4317884301C15744967 @default.
• W4317884301 hasConceptScore W4317884301C166957645 @default.
• W4317884301 hasConceptScore W4317884301C180747234 @default.
• W4317884301 hasConceptScore W4317884301C197934379 @default.
• W4317884301 hasConceptScore W4317884301C2524010 @default.
• W4317884301 hasConceptScore W4317884301C2779356329 @default.
• W4317884301 hasConceptScore W4317884301C2779530757 @default.
• W4317884301 hasConceptScore W4317884301C33923547 @default.
• W4317884301 hasConceptScore W4317884301C41008148 @default.
• W4317884301 hasConceptScore W4317884301C4438859 @default.
• W4317884301 hasConceptScore W4317884301C509550671 @default.
• W4317884301 hasConceptScore W4317884301C56739046 @default.
• W4317884301 hasConceptScore W4317884301C57658597 @default.
• W4317884301 hasConceptScore W4317884301C71008984 @default.
• W4317884301 hasConceptScore W4317884301C71924100 @default.
• W4317884301 hasConceptScore W4317884301C95457728 @default.
• W4317884301 hasConceptScore W4317884301C98274493 @default.
• W4317884301 hasLocation W43178843011 @default.
• W4317884301 hasLocation W43178843012 @default.

• next